secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-254959
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avita Medical terminates CEO Michael Perry, appoints James Corbett as President and CEO
--------------------------------------------------------------------------------

- Dr. Michael Perry terminated as President and CEO effective Sept 28, 2022; he remains a director.
- James Corbett appointed President and CEO; previously a non-executive director since July 2021.
- Corbett receives $600,000 annual base salary, $1M stock option grant (4-year vest), target bonus 60%.
- Corbett has ~40 years med device experience, CEO of Microtherapeutics, ev3, Alphatec Spine.
- Initial employment term of 3 years with automatic one-year renewals; Corbett also joins Board as executive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522254959/0001193125-22-254959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522254959/d406535d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-254959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer